TTR and Familial transthyretin-related amyloidosis: The GenomicsFirst Committee recommended the addition of hATTR based on the high prevalence and clinical impact of TTR V142I in BioMe [15], review of the Clinical Genome Resource (ClinGen) Actionability Adult Summary Report [23, 24], availability of new non-invasive procedures for the diagnosis of cardiac amyloidosis [25], FDA approval of new therapies for cardiac and neuropathic transthyretin amyloidosis [16, 26, 27], and the availability of expert multidisciplinary clinical care for amyloidosis at MSHS.